BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2025
0mins
Source: Newsfilter
Positive Opinion for TEVIMBRA: The European Medicines Agency's CHMP has issued a positive opinion recommending the approval of TEVIMBRA (tislelizumab) in combination with chemotherapy as a first-line treatment for extensive-stage small cell lung cancer, based on significant overall survival benefits demonstrated in the RATIONALE-312 study.
Impact on Cancer Treatment: The results from the study indicate a median overall survival of 15.5 months for patients receiving TEVIMBRA plus chemotherapy compared to 13.5 months for those on placebo, highlighting the potential of this treatment to improve outcomes for patients with this aggressive form of lung cancer.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ONC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ONC
Wall Street analysts forecast ONC stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 263.610
Low
385.00
Averages
403.76
High
424.00
Current: 263.610
Low
385.00
Averages
403.76
High
424.00
About ONC
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BRUKINSA Shows Long-Term Efficacy in Patients Over 80
- Sustained Efficacy: Nearly two-thirds of patients aged 80 and older treated with BRUKINSA remained progression-free after nearly 6.5 years, demonstrating the drug's effectiveness and tolerability in high-risk groups, reinforcing its role as the foundational BTK inhibitor.
- Clinical Data Highlights: The SEQUOIA subgroup analysis revealed a median age of 81 years with a 100% overall response rate and a 72-month progression-free survival rate of 63.8%, indicating BRUKINSA's therapeutic potential in elderly patients, particularly those with high-risk features.
- Safety Analysis: BRUKINSA exhibited consistent safety profiles in long-term follow-ups, particularly in older patients, with low rates of atrial fibrillation enhancing confidence in its use as a first-line treatment, supporting clinical decision-making.
- Patient Decision Factors: Recent studies indicate that safety, disease severity, and efficacy are the primary considerations for patients choosing first-line CLL treatments, while treatment duration is less influential, highlighting the importance of aligning treatment discussions with patient priorities.
See More
BeOne Medicines Stock Shows Oversold Signal
- Oversold Indicator: BeOne Medicines Ltd (Ticker: ONC) hit an RSI of 28.9 during Thursday's trading, indicating an oversold condition with a low price of $253.9475, suggesting that recent heavy selling may be exhausting.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 51.5, ONC's oversold status could attract bullish investors looking for buying opportunities, reflecting a divergence in market sentiment.
- Price Fluctuation: ONC's 52-week low is $239.25 and high is $385.22, with the latest trade at $260.31, indicating potential for price rebound within its trading range.
- Investor Focus: Investors may pay attention to ONC's oversold signal to identify potential buying opportunities, aiming to capitalize on gains when the market rebounds.
See More
BeOne Medicines Presents New Data at ASCO Meeting
- Clinical Data Unveiled: BeOne showcased new data from three priority programs at the 2026 ASCO Annual Meeting, highlighting significant advancements in its oncology pipeline, which are expected to propel multiple assets into pivotal trial phases.
- CDK4 Inhibitor Excels: BGB-43395 demonstrated a confirmed overall response rate of 68.4% in 1L HR+/HER2- metastatic breast cancer, with a favorable safety profile when combined with letrozole, supporting its application in a global randomized Phase 3 clinical trial.
- B7-H4 ADC Shows Promise: BG-C9074 achieved a confirmed overall response rate of 45.5% in ovarian cancer and 40.0% in triple-negative breast cancer, indicating early efficacy across different tumor types and supporting further development efforts.
- GPC3x4-1BB Bispecific Breakthrough: BGB-B2033 exhibited a confirmed overall response rate of 28.9% in heavily pre-treated hepatocellular carcinoma patients, with a favorable safety profile, positioning it for rapid clinical development aimed at establishing a new standard of care in challenging cancers.
See More
BeOne's Drug Shows New Breakthroughs in CLL Treatment
- Long-Term Efficacy Data: The SEQUOIA study indicates that BRUKINSA shows a progression-free survival (PFS) of 71.8% after a median follow-up of 84.01 months, significantly outperforming the 31.0% PFS of the BR group, highlighting its long-term efficacy in first-line treatment for chronic lymphocytic leukemia (CLL).
- Real-World Evidence: An analysis of 10,523 CLL/SLL patients treated with BTK inhibitors revealed that BRUKINSA significantly reduced the risk of death and treatment discontinuation, further solidifying its position as the best-in-class BTK inhibitor.
- Combination Therapy Potential: The combination of BRUKINSA with the next-generation BCL2 inhibitor sonrotoclax demonstrated an unprecedented overall response rate of 100% and a complete response rate of 59.5% in high-risk CLL patients, indicating a promising direction for time-limited treatments.
- Safety Consistency: The safety profile of BRUKINSA remains consistent with previous studies, with no new safety signals identified, ensuring its sustainability and patient confidence in clinical applications.
See More
TEVIMBRA and ZIIHERA Combination Therapy Significantly Improves Survival Rates
- Significant Survival Improvement: The HERIZON-GEA-01 trial demonstrated that the combination of TEVIMBRA and ZIIHERA with chemotherapy achieved a median overall survival of 26.4 months, compared to 19.2 months in the control group, indicating the potential importance of this combination in treating HER2+ gastroesophageal adenocarcinoma.
- Effective Regardless of PD-L1 Status: Results showed that this combination therapy provided significant survival benefits in both PD-L1 positive and negative patients, particularly in those with PD-L1 <1%, where the median survival was 29.7 months, far exceeding the control group's 15.8 months, highlighting its broad applicability.
- Strong Durability of Response: The median duration of response for the ZIIHERA and TEVIMBRA combination was 20.7 months, significantly longer than the 14.3 months for ZIIHERA alone and 8.3 months for the control group, underscoring the clinical significance of this combination in prolonging patient survival.
- Regulatory Progress: The U.S. FDA has accepted a supplemental Biologics License Application for TEVIMBRA with priority review, and the Chinese NMPA has also accepted applications for ZIIHERA and TEVIMBRA, indicating that this combination therapy is poised for rapid approval in multiple markets.
See More
BeOne Medicines to Participate in Goldman Sachs Healthcare Conference
- Conference Participation: BeOne Medicines will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, featuring a fireside chat at 10:00 a.m. EDT, showcasing its latest advancements in oncology treatments.
- Live Webcast Details: The event will be accessible via a live webcast from the investor section of the company's website, ensuring global investors can stay updated in real-time, with an archived version available post-event to enhance information transparency.
- Company Overview: BeOne Medicines is a global oncology company focused on developing innovative treatments for cancer patients, with a portfolio that spans hematology and solid tumors, indicating a broad strategic focus in the oncology sector.
- Global Team Expansion: The company boasts a growing global team across six continents, dedicated to scientific excellence and rapid response, reflecting its strategic importance in delivering treatments to patients more efficiently worldwide.
See More
BRUKINSA Shows Long-Term Efficacy in Patients Over 80
- Sustained Efficacy: Nearly two-thirds of patients aged 80 and older treated with BRUKINSA remained progression-free after nearly 6.5 years, demonstrating the drug's effectiveness and tolerability in high-risk groups, reinforcing its role as the foundational BTK inhibitor.
- Clinical Data Highlights: The SEQUOIA subgroup analysis revealed a median age of 81 years with a 100% overall response rate and a 72-month progression-free survival rate of 63.8%, indicating BRUKINSA's therapeutic potential in elderly patients, particularly those with high-risk features.
- Safety Analysis: BRUKINSA exhibited consistent safety profiles in long-term follow-ups, particularly in older patients, with low rates of atrial fibrillation enhancing confidence in its use as a first-line treatment, supporting clinical decision-making.
- Patient Decision Factors: Recent studies indicate that safety, disease severity, and efficacy are the primary considerations for patients choosing first-line CLL treatments, while treatment duration is less influential, highlighting the importance of aligning treatment discussions with patient priorities.
See More
BeOne Medicines Stock Shows Oversold Signal
- Oversold Indicator: BeOne Medicines Ltd (Ticker: ONC) hit an RSI of 28.9 during Thursday's trading, indicating an oversold condition with a low price of $253.9475, suggesting that recent heavy selling may be exhausting.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 51.5, ONC's oversold status could attract bullish investors looking for buying opportunities, reflecting a divergence in market sentiment.
- Price Fluctuation: ONC's 52-week low is $239.25 and high is $385.22, with the latest trade at $260.31, indicating potential for price rebound within its trading range.
- Investor Focus: Investors may pay attention to ONC's oversold signal to identify potential buying opportunities, aiming to capitalize on gains when the market rebounds.
See More
BeOne Medicines Presents New Data at ASCO Meeting
- Clinical Data Unveiled: BeOne showcased new data from three priority programs at the 2026 ASCO Annual Meeting, highlighting significant advancements in its oncology pipeline, which are expected to propel multiple assets into pivotal trial phases.
- CDK4 Inhibitor Excels: BGB-43395 demonstrated a confirmed overall response rate of 68.4% in 1L HR+/HER2- metastatic breast cancer, with a favorable safety profile when combined with letrozole, supporting its application in a global randomized Phase 3 clinical trial.
- B7-H4 ADC Shows Promise: BG-C9074 achieved a confirmed overall response rate of 45.5% in ovarian cancer and 40.0% in triple-negative breast cancer, indicating early efficacy across different tumor types and supporting further development efforts.
- GPC3x4-1BB Bispecific Breakthrough: BGB-B2033 exhibited a confirmed overall response rate of 28.9% in heavily pre-treated hepatocellular carcinoma patients, with a favorable safety profile, positioning it for rapid clinical development aimed at establishing a new standard of care in challenging cancers.
See More
BeOne's Drug Shows New Breakthroughs in CLL Treatment
- Long-Term Efficacy Data: The SEQUOIA study indicates that BRUKINSA shows a progression-free survival (PFS) of 71.8% after a median follow-up of 84.01 months, significantly outperforming the 31.0% PFS of the BR group, highlighting its long-term efficacy in first-line treatment for chronic lymphocytic leukemia (CLL).
- Real-World Evidence: An analysis of 10,523 CLL/SLL patients treated with BTK inhibitors revealed that BRUKINSA significantly reduced the risk of death and treatment discontinuation, further solidifying its position as the best-in-class BTK inhibitor.
- Combination Therapy Potential: The combination of BRUKINSA with the next-generation BCL2 inhibitor sonrotoclax demonstrated an unprecedented overall response rate of 100% and a complete response rate of 59.5% in high-risk CLL patients, indicating a promising direction for time-limited treatments.
- Safety Consistency: The safety profile of BRUKINSA remains consistent with previous studies, with no new safety signals identified, ensuring its sustainability and patient confidence in clinical applications.
See More
TEVIMBRA and ZIIHERA Combination Therapy Significantly Improves Survival Rates
- Significant Survival Improvement: The HERIZON-GEA-01 trial demonstrated that the combination of TEVIMBRA and ZIIHERA with chemotherapy achieved a median overall survival of 26.4 months, compared to 19.2 months in the control group, indicating the potential importance of this combination in treating HER2+ gastroesophageal adenocarcinoma.
- Effective Regardless of PD-L1 Status: Results showed that this combination therapy provided significant survival benefits in both PD-L1 positive and negative patients, particularly in those with PD-L1 <1%, where the median survival was 29.7 months, far exceeding the control group's 15.8 months, highlighting its broad applicability.
- Strong Durability of Response: The median duration of response for the ZIIHERA and TEVIMBRA combination was 20.7 months, significantly longer than the 14.3 months for ZIIHERA alone and 8.3 months for the control group, underscoring the clinical significance of this combination in prolonging patient survival.
- Regulatory Progress: The U.S. FDA has accepted a supplemental Biologics License Application for TEVIMBRA with priority review, and the Chinese NMPA has also accepted applications for ZIIHERA and TEVIMBRA, indicating that this combination therapy is poised for rapid approval in multiple markets.
See More
BeOne Medicines to Participate in Goldman Sachs Healthcare Conference
- Conference Participation: BeOne Medicines will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, featuring a fireside chat at 10:00 a.m. EDT, showcasing its latest advancements in oncology treatments.
- Live Webcast Details: The event will be accessible via a live webcast from the investor section of the company's website, ensuring global investors can stay updated in real-time, with an archived version available post-event to enhance information transparency.
- Company Overview: BeOne Medicines is a global oncology company focused on developing innovative treatments for cancer patients, with a portfolio that spans hematology and solid tumors, indicating a broad strategic focus in the oncology sector.
- Global Team Expansion: The company boasts a growing global team across six continents, dedicated to scientific excellence and rapid response, reflecting its strategic importance in delivering treatments to patients more efficiently worldwide.
See More
